-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 83c, provides guidance
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 17c ; Offers Guidance
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 9c ; Offers Guidance
-
-
-
-
-
-
-
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
-
-
-
-
-
-
-
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c
-
1,198,814 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

